pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda recalls·4d ago·3 min read
save

BD Issues Nationwide Recall for Specific Lots of BD® Intraosseous Vascular Access System Needle Sets Due to Reports of Difficulty Removing the Obturator

FRANKLIN LAKES, N.J. (July 31, 2026) – BD (Becton, Dickinson and Company) is voluntarily recalling specific lots of BD® Intraosseous Vascular Access System Needle Sets to the user level. These products are being recalled following reports that some users experienced difficulty removing the obturato

Jul 30, 2026·read at fda recalls ↗

Summary Company Announcement Date: July 30, 2026 FDA Publish Date: August 03, 2026 Product Type: Medical Devices Reason for Announcement: Recall Reason Description Due to Reports of Difficulty Removing the Obturator Company Name: (Becton, Dickinson and Company) Brand Name: Brand Name(s) BD Product Description: Product Description Intraosseous Vascular Access System Needle Sets Company Announcement FRANKLIN LAKES, N.J. (July 31, 2026) – BD (Becton, Dickinson and Company) is voluntarily recalling specific lots of BD® Intraosseous Vascular Access System Needle Sets to the user level. These products are being recalled following reports that some users experienced difficulty removing the obturator (stylet) after placement of the needle set.

Based on complaint reports, bench testing completed by BD and clinical observations, this may occur if the drill is not pulled straight back during insertion or if the obturator is incorrectly rotated during removal.The affected lots were manufactured with out of tolerance dimensions and distributed between September 30, 2024, and June 12, 2026. This recall does not affect the BD® Intraosseous Powered Driver.Risk Statement: If the obturator cannot be removed, the clinician may need to obtain a new IO needle or alternative vascular access device, such as a Peripheral IV catheter, potentially delaying therapy initiation. Patients at greatest risk are critically ill individuals requiring urgent vascular access, including out-of-hospital cardiac arrest and severe trauma patients.

Delays to therapy initiation may result in serious injury or death. Through June 2026, BD has received 75 complaints and reported 45serious injury reports. BD has also reported 4 deaths in which the inability to remove the stylet occurred during resuscitation efforts for out-of-hospital cardiac arrests.Product NameCatalogNo.Lot No.UDI-DIExpirationDateProductPackage SizeNeedle Kit for Powered Driver 15mm x 15GaD015151NKSee Appendix 1in customerletter*00801741163586See Appendix 1in customerletter*6 kits per caseNeedle Kit for PoweredDriver 25mm x 15GaD015251NK00801741163678Needle Kit for Powered Driver 35mm x 15GaD015351NK00801741163593Needle Kit for Powered Driver 45mm x 15GaD015451NK00801741163609Needle Kit for Powered Driver 55mm x 15GaD015551NK00801741163616*Additional information can be found in the customer letter, available here.BD is notifying its customers and distributors who may have received these lots of product directly.

Customers and distributors should immediately discontinue use of these lots and destroy all affected needle sets in accordance with their facility’s process.BD will issue replacement for destroyed product of the affected lot numbers to customers that purchased the affected product directly from BD, following receipt of the completed Customer Response Form.BD has identified the root cause of this issue and implemented corrective and preventative action, including product and labeling improvements, to enhance device robustness and reduce the likelihood of recurrence. Product distributed outside of the affected production window is not impacted.Customer inquiries related to this recall, as well as adverse reaction/events experienced with the product, should be addressed to BD’s North American Regional Complaint Center: 1-844-823-5433 (Toll Free) Monday – Friday between the hours of 8 a.m. and 5 p.m.

CT or by emailing: productcomplaints@bd.com.FDA MedWatch ReportingAdverse reactions/events experienced with the use of any of these products should also be reported to the FDA's MedWatch Adverse Event Reporting program either online, phone or by regular mail.Complete and submit the report Online: www.fda.gov/medwatch/report.htmCall 1-800-FDA-1088 (1-800-332-1088)Regular Mail: MedWatch, HF-2, FDA, 5600 Fisher’s Lane, Rockville, MD 20852-9787The U.S. Food and Drug Administration (FDA) has been notified of this recall.# # #About BDBD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients.

Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.Contacts:MediaMatt MarcusVP, Public RelationsMatt.Marcus@bd.comInvestorsShawn BevecSVP, Investor RelationsInvestor_Relations@bd.com Company Contact Information Consumers: BD’s North American Regional Complaint Center 1-844-823-5433 productcomplaints@bd.com Media: Matt Marcus VP, Public Relations Matt.Marcus@bd.com

source

Reporting by fda recalls.

read at fda recalls ↗
685 words · retrieved 49m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Recall5

related stories

  • Jul 24STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and moreSTAT
  • Jul 21Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengeFierce Biotech
  • Jul 21STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and moreSTAT
  • Jul 21A renewed push from the right against abortion pillsSTAT
  • Jul 20FDA still focused on lettuce supplier as source of parasite, despite faulty test resultSTAT